BRPI0016231B8 - composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo - Google Patents

composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo

Info

Publication number
BRPI0016231B8
BRPI0016231B8 BRPI0016231A BR0016231A BRPI0016231B8 BR PI0016231 B8 BRPI0016231 B8 BR PI0016231B8 BR PI0016231 A BRPI0016231 A BR PI0016231A BR 0016231 A BR0016231 A BR 0016231A BR PI0016231 B8 BRPI0016231 B8 BR PI0016231B8
Authority
BR
Brazil
Prior art keywords
digestive tract
ameliorating
risks
compositions
treating
Prior art date
Application number
BRPI0016231A
Other languages
English (en)
Other versions
BR0016231A (pt
BRPI0016231B1 (pt
Inventor
M Anderson David
W Fodge Douglas
Hsiao Humg-Yu
Liu Lin
Original Assignee
Chemgen Corp
Elanco Us Inc
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617824&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0016231(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemgen Corp, Elanco Us Inc, Lilly Co Eli filed Critical Chemgen Corp
Publication of BR0016231A publication Critical patent/BR0016231A/pt
Publication of BRPI0016231B1 publication Critical patent/BRPI0016231B1/pt
Publication of BRPI0016231B8 publication Critical patent/BRPI0016231B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteína ou carboidrato de superfície celular para ser usada no tratamento de infecções". enzimas de uma classe particular, caracterizadas pela capacidade de clivar uma ligação que efetua a liberação de uma proteína ou carboidrato de superfície celular, que não contêm um agente antiinfecção, apresentam significativa atividade antiinfecciosa. sob administração oral, essas enzimas são eficazes, por exemplo, no tratamento de infecções do trato digestivo em humanos e em animais. posteriormente, há benefícios de uma taxa de crescimento, eficácia de alimento, e saúde gerais significativamente aumentadas.
BRPI0016231A 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo BRPI0016231B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16993599P 1999-12-10 1999-12-10
PCT/US2000/033466 WO2001041785A2 (en) 1999-12-10 2000-12-08 Enzyme treatment for infection

Publications (3)

Publication Number Publication Date
BR0016231A BR0016231A (pt) 2003-06-24
BRPI0016231B1 BRPI0016231B1 (pt) 2016-10-04
BRPI0016231B8 true BRPI0016231B8 (pt) 2021-05-25

Family

ID=22617824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0016231A BRPI0016231B8 (pt) 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo

Country Status (31)

Country Link
US (2) US6780628B2 (pt)
EP (1) EP1239872B1 (pt)
JP (1) JP4871473B2 (pt)
KR (1) KR100639746B1 (pt)
CN (3) CN102172262B (pt)
AR (2) AR026764A1 (pt)
AT (1) ATE481981T1 (pt)
AU (1) AU782831B2 (pt)
BR (1) BRPI0016231B8 (pt)
CA (1) CA2394856C (pt)
CL (1) CL2008000057A1 (pt)
CO (1) CO5280226A1 (pt)
CR (1) CR6674A (pt)
CZ (1) CZ304925B6 (pt)
DE (1) DE60045010D1 (pt)
DK (1) DK1239872T3 (pt)
ES (1) ES2353371T3 (pt)
HU (1) HU230301B1 (pt)
IL (2) IL150048A0 (pt)
IN (1) IN247731B (pt)
MX (1) MX264033B (pt)
MY (1) MY124714A (pt)
NZ (1) NZ519404A (pt)
PH (1) PH12000003381B1 (pt)
PL (1) PL203054B1 (pt)
PT (1) PT1239872E (pt)
RU (1) RU2272419C2 (pt)
SK (1) SK287956B6 (pt)
TW (1) TWI255189B (pt)
UA (1) UA78486C2 (pt)
WO (1) WO2001041785A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
EP1812550A2 (en) * 2004-10-20 2007-08-01 Iogenetics, Llc Biocides
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
NZ569186A (en) 2005-12-15 2011-09-30 Chemgen Corp Enzymes for reduced immunological stress
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
RU2474587C2 (ru) * 2007-06-08 2013-02-10 Острэйлиан Паултри Срс Пти Лтд КЛОСТРИДИАЛЬНЫЙ ТОКСИН NetB
JP5427789B2 (ja) * 2007-12-20 2014-02-26 ダニスコ・ユーエス・インク バイオフィルムの酵素的予防及び制御
PL2254591T3 (pl) * 2008-02-08 2018-01-31 Prothera Inc Inhibicja i leczenie biofilmów żołądkowo-jelitowych
IN2014MN01722A (pt) 2012-02-16 2015-05-29 Lilly Co Eli
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
TWI656872B (zh) 2014-11-13 2019-04-21 美商益農美國公司 甲基鹽黴素於豬飼料中之抗病毒效果
ES2799515T3 (es) 2015-05-22 2020-12-18 Dmitry Dmitrievich Genkin ADN extracelular como una diana terapéutica en la neurodegeneración
CN106119221A (zh) * 2016-06-28 2016-11-16 浙江省农业科学院 磷脂酰肌醇特异性磷脂酶c基因、载体、工程菌及应用
CN106318925B (zh) * 2016-08-19 2021-04-02 浙江省农业科学院 利用枯草芽孢杆菌高效表达pi-plc基因的方法
CN106615691B (zh) * 2016-10-11 2019-07-02 上海国龙生物技术集团有限公司 一种抗感染酶复合剂及其在饲料中的应用
US10501730B2 (en) * 2017-05-30 2019-12-10 Ab Enzymes Oy Mannanase variants
KR20200122320A (ko) 2018-01-16 2020-10-27 씨엘에스 테라퓨틱스 리미티드 데옥시리보뉴클레아제 (dnase) 활성을 갖는 효소의 간 발현에 의한 질환의 치료
RU2020129391A (ru) * 2018-03-02 2022-03-09 Эвоник Оперейшенс ГмбХ Способ in vitro выявления недостаточности кишечного барьера у животных
RU2720471C1 (ru) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Кормовая добавка для цыплят-бройлеров

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
JPS5534039A (en) 1978-08-30 1980-03-10 Hiroo Ikezawa Preparation of phsophatidylinositol phospholipase c from bacillus thuringiensis
EP0229810B1 (en) 1985-07-09 1991-10-16 Quadrant Bioresources Limited Protection of proteins and the like
US4877738A (en) 1986-07-25 1989-10-31 Wisconsin Alumni Research Foundation Biological control of damping off and root rot and inoculum preparation therefor
US5049379A (en) 1987-07-27 1991-09-17 Wisconsin Alumni Research Foundation Fungicidal toxin and method and inoculum for controlling root rot and damping off
JPH0338530A (ja) * 1989-07-03 1991-02-19 Ajinomoto Co Inc 抗真菌剤
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ES2114889T3 (es) 1990-05-29 1998-06-16 Chemgen Corp Suplemento de semicelulasa que mejora el rendimiento energetico de alimentos que contienen hemicelulosa y producto alimentario para animales.
EP0477739A3 (en) 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
JPH07184642A (ja) * 1993-12-27 1995-07-25 Toagosei Co Ltd ホスホリパーゼｃの生産方法
NL1003096C2 (nl) 1995-05-15 1996-11-19 Gist Brocades Bv Application of phospholipases in animal feed.
EP0743017B1 (en) * 1995-05-15 2004-09-29 DSM IP Assets B.V. Application of phospholipases in animal feed
JPH08332032A (ja) * 1995-06-12 1996-12-17 Showa Denko Kk 動物経口物用酵素剤及びその用途
JP3914585B2 (ja) * 1995-10-19 2007-05-16 イーエヌ大塚製薬株式会社 マクロファージ一酸化窒素産生亢進剤
US6162473A (en) * 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
CN1092495C (zh) * 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
JPH1045581A (ja) * 1996-07-29 1998-02-17 Hideyo Yamaguchi 好中球機能低下抑制剤又は感染防御剤
EP0948608A1 (en) * 1996-10-31 1999-10-13 Novo Nordisk A/S Novel phospholipase, production and use thereof
SK5022001A3 (en) 1998-10-15 2001-09-11 Dsm Nv Antimicrobial enzymes in animal feed
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US20020116029A1 (en) * 2001-02-20 2002-08-22 Victor Miller MRI-compatible pacemaker with power carrying photonic catheter and isolated pulse generating electronics providing VOO functionality

Also Published As

Publication number Publication date
US6780628B2 (en) 2004-08-24
US7723091B2 (en) 2010-05-25
PT1239872E (pt) 2010-12-03
EP1239872A2 (en) 2002-09-18
ATE481981T1 (de) 2010-10-15
PL356175A1 (en) 2004-06-14
HU230301B1 (hu) 2015-12-28
IL150048A0 (en) 2002-12-01
TWI255189B (en) 2006-05-21
CL2008000057A1 (es) 2008-03-14
DK1239872T3 (da) 2010-10-25
JP2003520207A (ja) 2003-07-02
AR089799A2 (es) 2014-09-17
CN102172262A (zh) 2011-09-07
CN102172262B (zh) 2014-03-05
NZ519404A (en) 2004-05-28
IN2002DE00585A (pt) 2009-03-20
PL203054B1 (pl) 2009-08-31
MXPA02005735A (es) 2003-10-14
CA2394856A1 (en) 2001-06-14
RU2272419C2 (ru) 2006-03-27
JP4871473B2 (ja) 2012-02-08
BR0016231A (pt) 2003-06-24
US20020048576A1 (en) 2002-04-25
SK287956B6 (sk) 2012-07-03
BRPI0016231B1 (pt) 2016-10-04
MX264033B (es) 2009-01-22
CN1433319A (zh) 2003-07-30
WO2001041785A2 (en) 2001-06-14
UA78486C2 (uk) 2007-04-10
CO5280226A1 (es) 2003-05-30
IN247731B (pt) 2011-05-13
AR026764A1 (es) 2003-02-26
CA2394856C (en) 2011-05-10
WO2001041785A3 (en) 2002-01-24
IL150048A (en) 2016-09-29
EP1239872B1 (en) 2010-09-22
AU782831B2 (en) 2005-09-01
CN101327320A (zh) 2008-12-24
HUP0203402A2 (hu) 2003-02-28
US20040223961A1 (en) 2004-11-11
PH12000003381B1 (en) 2010-04-16
ES2353371T3 (es) 2011-03-01
AU2577601A (en) 2001-06-18
MY124714A (en) 2006-06-30
KR20020069204A (ko) 2002-08-29
SK8262002A3 (en) 2002-12-03
CZ20022007A3 (cs) 2002-11-13
DE60045010D1 (de) 2010-11-04
CZ304925B6 (cs) 2015-01-28
KR100639746B1 (ko) 2006-10-30
HUP0203402A3 (en) 2004-12-28
CR6674A (es) 2007-02-22

Similar Documents

Publication Publication Date Title
BRPI0016231B8 (pt) composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo
BR0007166A (pt) Método para aumentar a atividade dos animais de estimação
DE69915458D1 (de) Dextran formulierungen zur behandlung entzündlicher gelenkerkrankungen
DE69533593D1 (de) Zubereitungen zur behandlung von gastrointestinalen störungen, welche arabinogalactan und polyphenole von larix enthalten.
BR0013010A (pt) Formulação de cloreto de sódio de moxifloxacina
HUP0100090A2 (hu) Szájápoló készítmények
BR0314511A (pt) Seleção e uso de bactérias de ácido lático para reduzir a inflamação causada por helicobater
DK0671942T3 (da) Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf
TR200400363T4 (tr) Antibiyotikten / Antibiyotiklerden oluşan bir preparatın imalatı ve kullanımı
IT1307850B1 (it) Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
DE60122672D1 (de) Zusammensetzung zur intestinalen verabreichung
IS2742B (is) Samsetning@sem@nær@yfir@basískan@svingómýelínasa@af@bakteríuuppruna@til@nota@sem@næringarfræðileg@efnablanda@@fæðubótarefni@eða@lyfjaafurð
CA2335308A1 (en) Protease containing hairball remedy and use thereof
BR0214835A (pt) Uso de microorganismos para distribuição direcionada de substâncias para partes especìficas do intestino
Lockhart et al. Antibiotic considerations in medically compromised patients
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
BR9811548A (pt) Secreções maternas imunes e seu uso no tratamento e/ou profilaxia de condições do corpo humano
AU5643299A (en) Humic acid and its use in the treatment of various conditions
WO1999012552A8 (en) 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
CA2301872A1 (en) 8a-azalides as veterinary antimicrobial agents
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
BR0308734A (pt) Composto, composição farmacêutica, uso do composto, e, método para prevenir ou tratar infecção
DE69330809T2 (de) Therapeutisches Agens für Neutropenie
TH54151B (th) การรักษาการติดเชื้อด้วยเอนไซม์
Pellegrin et al. Response to infection in patients with acute leukemia during remission induction treatment: Ceftazidime versus cefotaxime+ tobramycin.

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELI LILLY AND COMPANY (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/12/2020